Trial
NCT07011849
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
Merck Sharp & Dohme LLC
Condition
Renal Cell Carcinoma
Intervention
Pembrolizumab
Why stopped
0 participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-13